INTRODUCTION
============

Bisphenol A (BPA) is a xenoestrogen and found in toys, drinking containers, dental sealants, water pipes, and food containers, including those with infant formula.[@B1][@B2][@B3][@B4][@B5][@B6] The primary route of exposure to BPA is through oral intake, but exposure can also occur via dermal contact or through inhalation.[@B3] BPA has been detected at higher concentrations in children than in adults, a finding that has been explained by children\'s greater food intake in proportion to body weight or variances in metabolism.[@B7][@B8] Reports of a relationship between BPA exposure and asthma-related consequences have been restricted to case reports of occupational asthma, especially among workers exposed to BPA in epoxy resins.[@B9][@B10] The actual pathogenesis of BPA metabolism and related allergic disease remains to be clarified. Increasing evidence suggests that BPA-induced damage results in oxidative stress within the targeted cells.[@B11] Disturbed oxidative homeostasis, through either in direct or indirect functional pathways, including mitochondrial function,[@B12] modulation of antioxidant enzymes, and increased thiobarbituric acid reactive substances, can be seen in the brain, kidney, and testis of mice exposed to BPA throughout the embryonic/fetal route.[@B13]

Prenatal exposure to BPA, followed by postnatal allergic sensitization and challenges, is considered to promote the development of experimental allergic asthma.[@B14] An association between increased odds ratio (OR) of a child developing wheeze before age 3 years and high (\>2.2 µg/g creatinine) maternal urinary BPA concentrations in gestational week 16 has been reported by Spanier et al.[@B15] Donohue et al.[@B16] performed the first cohort study to report an association between postnatal urinary BPA concentrations and asthma in young children. They found that urinary BPA concentrations at ages 3, 5, and 7 years were associated with asthma assessed between 5 to 12 years of age. We also previously reported that early-life BPA exposure may increase the risk of atopic disorders.[@B17] These findings add to the suspicion that environmental exposure to BPA might be associated with adverse respiratory outcomes in early childhood and may contribute to the risk of developing asthma in later life.

Airflow limitation and airway remodeling in asthma can result from an imbalance in redox systems favoring an oxidative environment.[@B18] Glutathione S-transferase (GST) is thought to be involved in detoxification of BPA metabolites and reactive oxygen species (ROS).[@B19] Several studies have also demonstrated that GST polymorphisms are associated with certain inflammatory diseases, including asthma.[@B20] *SOD2* rs4880, *EPHX1* rs2740171, and *GSTP1* rs1695 variants were also found to be highly associated with diisocyanate-induced asthma.[@B21] This association with isocyanate-induced asthma supports the hypothesis that genetic variability within antioxidant defense systems may provide an environmental mechanism for developing asthma.[@B21] In addition, related to other exposures, *GSTM1* null and *GSTP1* Ile105Val genotypes have been described to be associated with increased susceptibility to diesel exhaust particles (DEPs) and ozone exposure.[@B22][@B23] Finally, the *SOD2* Ala allele has been reported to be linked to childhood asthma.[@B24]

Therefore, we tested a possible association between exposure to BPA and genes involved in oxidative ROS in a case-control study on asthma. First, in a screening step we will evaluate whether genetic polymorphisms of oxidative stress markers, *GSTM1*, *GSTP1*, *SOD2*, catalase (*CAT*), myeloperoxidase (*MPO*), and *EPHX1* are related to a higher urine concentration of BPA metabolites. Second, for identified oxidative stress genes we will determine whether these modify the association of BPA exposure with asthma.

MATERIALS AND METHODS
=====================

Study population
----------------

We conducted a case-control study comprised of 126 asthmatic children and 327 controls. Three control subjects were matched to each case subject by date of enrollment (within 3 months) if both had urine specimens and oral scrapes. All of the children were part of the Childhood Environment and Allergic diseases Study (CEAS) cohort recruited in 2010.[@B25] Full enrollment in the study required the completion of BPA exposure monitoring of urine BPA metabolite levels and genotyping. At age 3 years, BPA metabolites were measured in urine samples, and genotyping was based on buccal cell samples. Parents were interviewed using a standardized questionnaire regarding basic demographics, birth history, parental age and education levels, family income, parental history of allergic diseases, duration of breast feeding, and environmental exposures of the child. Information about asthma was also collected. Written informed consent was obtained from all parents. Taipei Hospital\'s Institutional Review Board approved the study protocol (TH-IRB-0014-0011), which complied with the principles of the Helsinki Declaration.

Questionnaire survey
--------------------

An International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire was used for collecting data on the children\'s allergic symptoms and information on duration of breast-feeding, number of older siblings, furry pets, carpets, or incensing at home, fungi at house walls, and tobacco smoke exposure were collected. The parents also answered a standardized questionnaire for basic demographics, birth history, parental history of allergic diseases, and family income.

Case definition
---------------

Asthma was determined by pediatric allergists based at least on one of the following 3 criteria: 1) recurrence of at least 2 of the 3 symptoms: cough, wheeze, and shortness of breath within the previous 12 months without having a cold, 2) physician\'s diagnosis of asthma with ongoing treatment, and 3) response to treatment with β~2~-agonists or inhaled corticosteroids.[@B26] Patients visiting the clinic without fulfilling the above criteria were defined as controls.

Laboratory methods
------------------

### Exposure monitoring

First mid-stream urine in the morning was collected from children at 3 years of age and stored at −20℃ until analysis. The urine samples were processed by solid-phase extraction. BPA metabolite (bisphenol A glucuronide \[BPAG\]) concentrations were determined using ultra-performance liquid chromatography/tandem mass spectrometry (UPLC-MS/MS) with isotopedilution techniques as described elsewhere.[@B27] The limit of detection (LOD) was 1.61 ng/mL. For concentrations below the detection limit, a value of half the LOD was assigned. All results involved duplicate analysis. Urine creatinine levels were analyzed by enzymatic assay (Cayman Chemical, Ann Arbor, MI, USA).[@B28] In all analyses, we adjusted for urine creatinine levels.

### Genotyping

Genomic DNA was extracted from oral epithelial cells using a Gentra Purgene DNA Buccal Cell Kit (QIAGEN Sciences, Germantown, MD, USA). Candidate genes were selected based on their functional role in oxidative stress and inflammation. Quick-SNP version 1.1 (Carlsbad, CA, USA) was used to select 9 tag single nucleotide polymorphisms (SNPs) within the candidate genes that had a minor allele frequency (MAF) \>5% and an r^2^\>0.8 in Asian populations.[@B29] The *GSTM1*, *GSTP1* (rs1695), *SOD2* (rs5746136), *SOD2* (rs4880), *CAT* (rs769218), *MPO* (rs2071409), *EPHX1* (rs1051740), and *EPHX1* (rs2740171) polymorphisms ([Supplementary Table 1](#S1){ref-type="supplementary-material"}), selected from hot spots of Asian populations on the National Center for Biotechnology information (NCBI) website, were analyzed by TaqMan SNP Genotyping Assay (ABI, Foster City, CA, USA) as described elsewhere.[@B30] In addition, a deletion (null-mutation) of the *GSTM1* gene was analyzed. All samples were measured using the same assay in duplicate to reduce the influence of unavoidable inter-assay variances. To control for errors and technical problems in genotyping, derived genotype frequencies were compared with the expected allelic population equilibrium based on the Hardy-Weinberg equilibrium test. Incomplete data missing at least 1 of 2 SNPs were excluded, and then individual haplotypes were estimated from genotype data.

Statistical analysis
--------------------

Baseline characteristics of the case and control subjects were compared using the 2-sample *t* test for continuous variables or χ^2^ tests for categorical variables. Differences in geometric means of BPA metabolite concentrations (BPAG) among different genotypes were analyzed using the analysis of covariance (ANCOVA) test. To correct the skewed distribution of BPAG, the variable is log-transformed (LnBPAG) or geometric means are presented. To study the potentially modifying effect of oxidative stress genes, we analyze genotypes in asthma cases and controls. To estimate associations of genetic variants with asthma, ORs with 95% confidence intervals (CIs) were calculated by logistic regression. We determined whether one of the oxidative stress genes had an effect on the distribution of BPAG. To analyze combined effects of BPAG and genes, we then focus on those genes that affected the BPAG distribution in children. Since BPAG concentration seems to depend on oxidative stress genotypes, we were not allowed to simply test the interaction of BPAG with the oxidative stress genotypes, as unbiased assessments of interaction need to be based on 2 independent variables.[@B31] To remove the dependency, we first regressed the BPAG levels on the oxidative stress genotypes and estimated the residuals of the BPAG concentration that is not explained by oxidative stress genotypes. Then, we tested the interaction of the BPAG residuals with the oxidative stress genes on asthma. The interactive effect was estimated only in the presence of statistically significant interaction term (*P*~interaction~≤0.05) as follows:

In all asthma models, potential confounders from literature reviews, such as gender, premature birth, maternal age and education, maternal history of atopy, family income, duration of breast feeding, number of older siblings, pet raising, environmental tobacco smoke (ETS) exposure, use of carpets at home, and fungi on house walls were taken into consideration. We adjusted for those confounders that resulted in a 10% change in point estimates when removed from the model. All hypothesis testing was 2-sided at a significance level of 0.05 and was performed with SAS software version 9.1 (SAS Institute, Cary, NC, USA).

RESULTS
=======

Data on the family and environmental characteristics of the cases and controls revealed no significant differences between the 2 groups, with the exception of maternal history of atopy and ETS exposure ([Table 1](#T1){ref-type="table"}). Distribution of BPAG levels are shown in [Supplementary Table 2](#S2){ref-type="supplementary-material"}.

BPAG levels and asthma
----------------------

The BPAG levels between asthma and controls was (geometric mean \[standard error {SE}\] 14.70 \[1.07\] vs 10.93 \[1.12\], *P*=0.019). Asthma was associated with the BPAG urine concentration (aOR, 1.29 per log unit increase in concentration; 95% CI, 1.08--1.55) ([Table 2](#T2){ref-type="table"}).

The association of BPAG levels with different genotypes
-------------------------------------------------------

Children with the *GSTP1* AA genotype had higher BPAG levels than GG carriers after adjusting for urine creatinine, age, gender, maternal history of atopy, and ETS exposure (geometric mean \[SE\] 12.72 \[4.16\] vs 11.42 \[2.82\]; *P*=0.036) ([Table 3](#T3){ref-type="table"}). No other oxidative stress gene affected the distribution of BPAG.

The association of different genotypes with asthma
--------------------------------------------------

Significant differences in genotype frequency were found between asthma cases and controls for *GSTP1* (rs1695), *SOD2* (rs5746136), and *EPHX1* (rs2740171) polymorphisms. *GSTP1* AA, *SOD2* TT, and *EPHX1* AA genotypes were associated with a higher risk of asthma with an aOR (95% CI) of 3.00 (1.23--7.33), 2.78 (1.54--5.02), and 2.07 (1.00--4.24), compared with the GG, CC, and CC genotypes, respectively ([Supplementary Table 3](#S3){ref-type="supplementary-material"}).

The association of genotypes and asthma stratified by BPAG levels
-----------------------------------------------------------------

We further investigated the association of genotypes and asthma stratified by median BPAG levels. However, in this analysis we focused on *GSTP1*, since the genetic polymorphism of this gene was only associated with BPAG levels. In children with high BPAG level ≥6.55 ng/mL, the *GSTP1* AA genotype was related to a higher odds of asthma than GG genotype (aOR, 4.84; 95% CI, 1.02--23.06) ([Table 4](#T4){ref-type="table"}). In children with BPAG level \<6.55 ng/mL, there was no statistical significance.

The combined effects of BPAG levels and genotypes on asthma
-----------------------------------------------------------

Further, since BPAG urine concentrations differ among genotypes of *GSTP1*, to analyze combined effects we focused on the interplay of *GSTP1* and BPAG with asthma. [Table 4](#T4){ref-type="table"} shows that the adverse effects of BPA exposure are largely restricted to children carrying the *GSTP1* AA genotype with higher BPAG levels. Residuals were estimated by subtracting the effect estimated for *GSTP1* (rs1695). This was necessary, since the independence criterion for combined effects requires that gene and environmental effects are not associated, which they were, as shown above. Further, since *GSTP1* was associated with asthma and BPAG levels differ among genotypes of *GSTP1* ([Table 3](#T3){ref-type="table"}), we focused on the interplay of *GSTP1* and BPAG levels with asthma. Before we can estimate whether there is an interaction between *GSTP1* and BPAG resulting in a higher odds of having asthma, we needed to estimate the part of BPAG that is not explained by *GSTP1* (the residuals). Then, we tested the interaction of the BPAG residuals with *GSTP1* gene on asthma. [Table 4](#T4){ref-type="table"} shows that the residual of BPAG in interaction with *GSTP1* statistically significantly increases the odds of asthma. To further demonstrate this effect in a simpler model, we stratified the BPAG median levels. In addition, we controlled for known confounding factors, such as urine creatinine, age, gender, maternal history of atopy, maternal education, and ETS exposure. In the stratified analysis ([Table 4](#T4){ref-type="table"}, upper part, stratified by the median of BPAG levels), we can see that among the cases with lower BPAG levels (≤6.55 ng/mL) there are 65.8% with the *GSTP1* AA genotype, similarly among the controls (63.7%). However, among cases with higher BPAG levels (\>6.55 ng/mL), there are 74.0% with the *GSTP1* AA genotype, but only 60.0% in the controls (OR, 4.84). From the lower half of [Table 4](#T4){ref-type="table"}, addressing the interaction on a multiplicative level, it is obvious that the OR for an individual with asthma is 2.92 times higher when both BPAG residual levels are higher and the child has a *GSTP1* AA genotype. The interaction term on a multiplicative level is not statistically significant. However, additive interaction, determined by stratification, provides a better idea of the public health importance of this combined effect (OR, 4.84).

DISCUSSION
==========

In this case-control study, we found an association between *GSTP1* AA genetic variants in asthmatic patients and higher urine BPA metabolite concentrations. To the best of our knowledge, the associations between oxidative stress genotypes and urine BPA metabolite levels in children with asthma have not been studied before. We found that children with *GSTP1* AA genotypes and higher urine BPA metabolite levels had 4.84-fold higher susceptibility to asthma. This finding supports our hypothesis that---assuming the *GSTP1* gene participates in detoxification of BPA metabolites---the polymorphism of genes coding for *GSTP1* may affect individual differences in urinary excretion of BPAG. Although a number of other studies supported a combined effect of BPA metabolites and *GSTP1* polymorphisms,[@B26] our findings need to be replicated in future studies, since we tested multiple oxidative stress genes and did not adjust for multiple testing in our case-control study. In addition, it is necessary to improve our understanding of the possible connection between exposure to environmental BPA, oxidative stress, and *GSTP1* polymorphism in the process of developing asthma.

Our findings add to the body of findings supporting an association between postnatal urine BPAG concentrations and asthma in young children reported by Kuo Chou et al.[@B24] and Bowler et al.[@B32] We also identified that higher urine BPAG concentrations were associated with asthma occurrence. These results add to the evidence that environmental exposure to BPA might be associated with adverse respiratory outcomes.

A growing body of findings suggests that BPA-induced damage is associated with oxidative stress.[@B26] The *GSTP1* gene variant has also been reported to have a significantly lower level of GST enzyme activity. Indeed, several studies have shown that *GST* polymorphisms are associated with some inflammatory diseases, including asthma.[@B33] Our analyses stratified by *GSTP1* genotypes revealed that children with the AA genotype had higher BPAG concentrations, especially children with asthma. However, direct evidence for exogenous exposure of BPA and urine metabolites, and its modulation by GSTP1 enzyme polymorphisms is scant.[@B34] The *GSTP1* gene plays a significant role in antioxidant defense mechanisms. The balance between regression and progression of inflammation after exposure to an environmental insult can be determined by these genes.[@B35] In zebrafish related to morphological changes, expression of the *GSTP1* gene was reported to be up-regulated by high concentrations of tamoxifen. Tamoxifen may reverse the effects of estradiol and BPA.[@B36] It has also been reported that BPA metabolites can be converted into glutathione conjugates in order to be excreted in urine. Thus, the expression of the *GSTP1* gene may be responsible for conjugation of BPA metabolites with glutathione, which could increase with BPA exposure.[@B37]

Numerous reports have suggested indirect associations of oxidative stress-related genes with asthma occurrence. Inhaled diesel exhaust particles, ETS, ozone, and mold can each confer an increased risk of asthma symptom exacerbation in carriers of the Val105 allele.[@B38][@B39] *GSTP1* polymorphisms have recently been reported to have a significant association with asthma risk.[@B40][@B41] Minor allele carriers of *GSTP1* rs1695 were also related to an increased risk of asthma in several different study populations. [@B38][@B42] Such traits were mainly manifested when children were exposed to ETS or to high levels of air pollution.[@B38][@B43] In this study, we found involvement of *GST*, *SOD2*, and *EPHX1* genetic polymorphisms in asthma, suggesting the hypothesis that genetic variability within antioxidant defense systems can contribute to the pathogenesis of this inflammatory disease.

Using stratification for high and low BPAG concentration, we found that the *GSTP1* AA genotype increased the odds of asthma in children with high BPAG concentrations. This supports the hypothesis that a less efficient defense against oxidative stress products may contribute to the pathogenesis of asthma. BPA is considered to induce oxidative stress by disrupting the activities of antioxidant enzymes.[@B44] In addition, it has been reported that variations in *SOD2*, *GST*, and *EPHX1* genes contribute to BPA susceptibility.[@B21] Then, oxidative stress may lead to airway inflammation and decrease pulmonary function as reported in rats exposed to pollutant mixtures.[@B45] In support of our findings, children living in high PM~10~ communities, the *GSTP1* Ile/Val or Val/Val genotype were the high-risk genotype for childhood asthma.[@B40] The Taiwan Children Health Study Group also reported that exposure to PM~2.5~ and O~3~ was associated positively with a greater risk of asthma among those with at least 1 Val105 allele of the *GSTP1* gene. In the Cincinnati Childhood Allergy and Air Pollution Study birth cohort, high exposure to DEP was associated with wheezing phenotypes only in children with the *GSTP1* Val105 allele (rs1695).[@B46]

*GSTP1* polymorphism has never been reported to modify the association of urine BPA metabolite levels and asthma. Also, the role of polymorphism of *GSTP1* in urine excretion of BPA metabolites has not been assessed to date. Our study was based on the hypothesis that if *GSTP1* participate in detoxification of BPA metabolites, the polymorphism of genes coding for *GSTP1* may affect individual differences in urine excretion of BPAG. This mechanism can be very similar to processes identified by the association between exogenous exposure of polycyclic aromatic hydrocarbons (PAHs) and urine metabolites and its modulation by *GSTP1* enzyme polymorphisms.[@B47] One hundred seventy German workers exposed to PAHs were surveyed by a cross-sectional study to explore the role of 11 polymorphisms of *CYP1A1*, *CYP1A2*, *CYP1B1*, *CYP3A4*, *EPHX1*, *GSTM1*, *GSTT1*, and *GSTP1* in the connection between occupational exposure to PAH and urine PAH metabolites. A significantly increased 1-OHP level was associated with *GSTP1* variants.

Some potential limitations may affect the conclusion of this study. First, our study was conducted using a targeted candidate gene approach. In the past, we relied on a prior understanding of the functional features of possible genetic candidates, which may result in blocking the detection of novel. However, prior knowledge helped us focus. Hence, we deliberately selected 7 candidate genes involved in the pathogenesis of oxidative pathways for screening and validation in this study. This focused approach was cost-effective compared to a genome-wide approach. Second, we are aware that BPA measurements in spot urine samples can be limited as other studies also have shown low intra-class correlation coefficient of spot urine sample. However, they are considered to adequately reflect average population exposure when sample sizes are large.[@B48] Moreover, other investigations showed that single spot samples obtained from children provided a reliable characterization of absolute and relative exposure over the short time window studied.[@B49] Moreover, the reliability of assessment of BPA metabolites was also enhanced by analyzing urine BPA metabolites using UPLC-MS/MS with decent validity.

We have strengthened our study using direct measurement of exposure through objective quantitative biomarkers for BPA metabolites and assessment of the outcome by physician diagnoses of asthma. We also intended to reduce the recall bias of exposure assessment derived from questionnaires by directly assessing BPA exposure through quantifying urine BPA metabolites. Thus, we were able to test for our genetic associations with adjustment for potential confounders, such as urine creatinine, age, gender, maternal history of atopy, maternal education, and ETS exposure.

In conclusion, this case-control study found that the *GSTP1* rs1695 variants are significantly associated with asthma particularly in children with higher BPA urine concentrations, thus supporting the hypothesis that genetic variability within antioxidant defense systems contributes to the pathogenesis of this disease. The oxidative stress gene *GSTP1* rs1695 polymorphism seems to modify the association of BPA exposures with asthma. Since adverse effects of BPA exposure were largely restricted to children carrying *GSTP1* AA genotypes, preventive measures to avoid BPA exposure should be introduced in these susceptible children. However, to reach a firm conclusion, future studies need to replicate our findings. In addition, there is a requirement to standardize methods for environmental exposure assessment.
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SUPPLEMENTARY MATERIALS
=======================

###### Supplementary Table 1

Candidate SNP and TaqMan assay information

###### Supplementary Table 2

Distribution of BPAG levels (ng/mL)

###### Supplementary Table 3

Association between different genotypes and asthma

###### Characteristics of the study population

![](aair-10-172-i001)

  Variables                              Total             Cases              Controls           *P* value
  -------------------------------------- ----------------- ------------------ ------------------ -----------
  Total No.                              453               126                327                
  Mother                                                                                         
   Maternal age (year)                   29.40±4.35        29.61±4.08         29.31±4.45         0.55
   Maternal education                                                                            
    High school and below                268 (59.2)        72 (67.9)          196 (69.5)         0.76
    College and above                    120 (26.5)        34 (32.1)          86 (30.5)          
   Maternal history of atopy (yes)       126 (27.8)        46 (36.5)          80 (24.5)          0.002^\*^
  Children                                                                                       
   Sex (male)                            261 (57.6)        76 (60.3)          185 (56.6)         0.47
   Birth weight (g)                      3,120.45±440.46   3,075.9 (381.79)   3,135.0 (461.56)   0.25
   Premature birth (\<37 weeks)          353 (77.9)        91 (72.2)          262 (80.1)         0.99
  Environmental factors                                                                          
   Older siblings (≥2)                   67 (14.8)         16 (12.7)          51 (15.6)          0.63
   Breast feeding (yes)                  292 (64.5)        75 (59.5)          217 (66.4)         0.41
   Pet raising (yes)                     70 (15.5)         21 (16.7)          49 (15.0)          0.51
   ETS exposure (yes)                    186 (41.1)        59 (46.8)          127 (38.8)         0.02^\*^
   Family income per year (US dollars)                                                           
    \<20,000                             110 (31.3)        25 (29.4)          85 (32.0)          0.80
    20,000--50,000                       213 (60.7)        52 (61.2)          161 (60.5)         
    \>50,000                             28 (8.0)          8 (9.4)            20 (7.5)           

Data are shown as number (%) or mean±SD. Some numbers do not add up to total number because of missing values.

ETS, environmental tobacco smoke; SD, standard deviation.

^\*^*P*\<0.05.

###### Association of urine BPAG levels (ng/mL) with asthma

![](aair-10-172-i002)

  Variables^\*^              LnBPAG^†^
  -------------------------- -------------------
  Asthma crude OR (95% CI)   1.21 (1.03--1.43)
  Asthma aOR (95% CI)        1.29 (1.08--1.55)

BPAG, bisphenol A glucuronide; OR, odds ratio; CI, confidence interval; aOR, adjusted odds ratio; ETS, environmental tobacco smoke.

^\*^Adjusted for urine creatinine, age, gender, maternal history of atopy, maternal education, and ETS exposure; ^†^*P*\<0.05.

###### Association of urine BPAG levels (ng/mL) with genotypes

![](aair-10-172-i003)

  SNPs                          No. (%)      GM (SE) BPAG
  ----------------------------- ------------ ------------------
  *GSTM1* (n=453)                            
   Present                      271 (59.8)   11.05 (3.14)
   Null                         182 (40.2)   12.46 (3.51)
  *GSTP1* (rs1695) (n=452)                   
   AA                           292 (64.6)   12.72 (4.16)^\*^
   AG                           110 (24.3)   11.66 (3.17)^\*^
   GG                           50 (11.1)    11.42 (2.82)^\*^
  *SOD2* (rs5746136) (n=453)                 
   CC                           182 (40.2)   11.68 (3.37)
   TC                           196 (43.3)   11.97 (3.42)
   TT                           75 (16.6)    12.13 (3.21)
  *SOD2* (rs4880) (n=451)                    
   AA                           318 (70.5)   11.90 (3.48)
   AG                           106 (23.5)   12.40 (3.14)
   GG                           27 (6.0)     9.48 (2.87)
  *CAT* (rs769218) (n=450)                   
   GG                           140 (31.1)   14.31 (3.60)
   AG                           215 (47.8)   11.21 (3.30)
   AA                           95 (21.1)    10.45 (3.13)
  *MPO* (rs2071409) (n=446)                  
   TT                           348 (78.0)   11.89 (3.46)
   GT                           81 (18.2)    11.13 (3.08)
   GG                           17 (3.8)     16.84 (3.15)
  *EPHX1* (rs1051740) (n=453)                
   TT                           135 (29.8)   11.67 (0.33)
   TC                           216 (47.7)   11.64 (3.25)
   CC                           102 (22.5)   12.66 (4.09)
  *EPHX1* (rs2740171) (n=445)                
   CC                           337 (75.7)   11.63 (3.32)
   AC                           74 (16.6)    12.91 (3.66)
   AA                           34 (7.6)     13.89 (3.12)

Stands for the single significantly higher concentration compared to the other genotype.

GM, geometric mean; SE, standard error; BPAG, bisphenol A glucuronide; SNP, single-nucleotide polymorphism.

^\*^*P*\<0.05.

###### The combined effects of BPAG levels and genotypes on asthma. The additive interaction of *GSTP1* genotype identified by stratification and BPAG median levels and the multiplicative interaction effect of the *GSTP1* gene and BPAG residuals on asthma

![](aair-10-172-i004)

  Variables                                                    Cases       Controls     β        OR (95% CI)             aOR (95% CI)^\*^        *P* value
  ------------------------------------------------------------ ----------- ------------ -------- ----------------------- ----------------------- -----------
  *GSTP1* (rs1695) (n=452)                                     126         326                                                                   
   AA                                                          87 (69.0)   205 (62.9)            2.61 (1.13--6.02)^†^    3.00 (1.23--7.33)^†^    
   AG                                                          32 (25.4)   78 (23.9)             2.52 (1.03--6.19)^†^    2.93 (1.13--7.59)^†^    
   GG                                                          7 (5.6)     43 (13.2)             1.00                    1.00                    
  Model 1 (stratification, interaction of an additive scale)                                                                                     
   BPAG≤6.55 ng/mL^‡^ (n=327)                                  76          251                                                                   
    *GSTP1*                                                                                                                                      
     AA                                                        50 (65.8)   160 (63.7)            1.94 (0.72--5.25)       1.20 (0.36--4.00)       
     AG                                                        21 (27.6)   60 (23.9)             2.17 (0.75--6.31)       1.86 (0.52--6.62)       
     GG                                                        5 (6.6)     31 (12.4)             1.00                    1.00                    
   BPAG\>6.55 ng/mL (n=125)                                    50          75                                                                    
    *GSTP1*                                                                                                                                      
     AA                                                        37 (74.0)   45 (60.0)             4.93 (1.04--23.45)^†^   4.84 (1.02--23.06)^†^   
     AG                                                        11 (22.0)   18 (24.0)             3.67 (0.69--19.56)      3.62 (0.68--19.35)      
     GG                                                        2 (4.0)     12 (16.0)             1.00                    1.00                    
  Model 2 (interaction on a multiplicative scale)                                                                                                
   *GSTP1* (rs1695)                                                                                                                              
    AA                                                                                  1.071    2.92 (1.00--8.55)                               0.05^†^
    AG                                                                                  1.039    2.83 (0.92--8.69)                               0.07
    GG                                                                                           1.000                                           
   Residuals of BPAG                                                                    −0.004   1.00 (0.97--1.02)                               0.73
   *GSTP1* (rs1695)×Residuals of BPAG                                                                                                            
    AA                                                                                  0.008    1.01 (0.98--1.03)                               0.52
    AG                                                                                  0.002    1.00 (0.98--1.03)                               0.87
    GG                                                                                           1.000                                           

Data are shown as number (%). Model 1 is *GSTP1* (rs1695) for BPAG\<6.55 ng/mL and/or ≥6.55 ng/mL, and model 2 is *GSTP1* (rs1695)+residuals of BPAG+*GSTP1* (rs1695)×residuals of BPAG.

BPAG, bisphenol A glucuronide; OR, odds ratio; CI, confidence interval; aOR, adjusted odds ratio.

^\*^Adjusted for urine creatinine, age, gender, maternal history of atopy, maternal education, and environmental tobacco smoke exposure; ^†^*P*\<0.05; ^‡^6.55 ng/mL is the median.
